Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:approves |
gptkb:2007
birth control |
| gptkbp:brand |
gptkb:Lybrel
|
| gptkbp:clinical_trial |
studied for efficacy
studied for safety studied for continuous use |
| gptkbp:contraindication |
gptkb:healthcare_organization
liver disease history of blood clots smoking over age 35 |
| gptkbp:dosage_form |
gptkb:tablet
0.02 mg ethinyl estradiol 0.09 mg levonorgestrel |
| gptkbp:duration |
24 hours
|
| gptkbp:form |
oral tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lybrel
|
| gptkbp:indication |
menstrual cycle regulation
|
| gptkbp:ingredients |
gptkb:ethinyl_estradiol
gptkb:levonorgestrel |
| gptkbp:is_effective_against |
91% with typical use
99% with perfect use |
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Wyeth_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
blister pack
|
| gptkbp:pharmacokinetics |
gptkb:drug
thickens cervical mucus inhibits ovulation alters endometrial lining |
| gptkbp:population |
available online
|
| gptkbp:previous_name |
levonorgestrel and ethinyl estradiol
|
| gptkbp:regulatory_compliance |
FDA approved
TGA approved Health Canada approved |
| gptkbp:replaced_by |
not withdrawn
|
| gptkbp:requires |
gptkb:theorem
|
| gptkbp:scholarships |
consult healthcare provider
|
| gptkbp:shelf_life |
check packaging
|
| gptkbp:side_effect |
gptkb:historical_event
headache nausea hypertension weight gain breast tenderness acne mood changes gallbladder disease thromboembolic disorders breakthrough bleeding migraine headaches amenorrhea |
| gptkbp:storage |
room temperature
away from moisture away from heat |
| gptkbp:bfsParent |
gptkb:ethinylestradiol
|
| gptkbp:bfsLayer |
6
|